Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Tysabri Concerns Continue to Weigh on Biogen, Elan
- EP Vantage submits: Despite reporting strong quarterly revenues and earnings ahead of Wall Street estimates, shares in Biogen Idec BIIB fell 7% Tuesday and continued to fall in yesterday, down even further to a two-year low of $40.72. With shares in one of Biogen Idec’s key partners, Elan ELN,...
- External links 2008-10-23
- Lundbeck's Late Stage Pipeline Keeps Looking Thinner
- EP Vantage submits: Lundbeck (HLUKY.PK) yesterday announced yet another setback to its late-stage pipeline, with the news that it and partner Solvay (SVYSY.PK) would be discontinuing development of anti-psychotic drug bifeprunox. While the news itself was not a massive surprise following an earlier failure of the drug as...
- External links 2009-07-31
- United Therapeutics: Gold Star Performance as Second FDA Approval Confirmed
- EP Vantage submits: If pharma companies had end of school awards before the summer holidays United Therapeutics UTHR would be lining up to get a well deserved gold star for achieving its goal of bagging two US approvals in the space of just eight weeks. On Friday, the FDA granted...
- External links 2009-08-02
- Once Again, Savient Disappoints Investors
- EP Vantage submits: Savient SVNT once again demonstrated its ability to disappoint investors, yesterday announcing that the FDA has refused to grant its new gout treatment, Krystexxa, a marketing license. The news prompted shares in the company to plunge 30% in early trade. Even though no further trials have been...
- External links 2009-08-04
- ViroPharma Finally Able to Look Forward
- EP Vantage submits: ViroPharma VPHM has lost a long-fought battle to keep generic versions of its top selling antibiotic, Vancocin, off the market, a disappointing outcome for the company, but one that was widely anticipated. The antibiotic has been hugely profitable for ViroPharma and a few more years of...
- External links 2009-08-06
- Onyx Signaling Appetite for Deals
- EP Vantage submits: Onyx Pharmaceuticals ONXX ruffled some feathers last week by announcing a fundraising effort to raise around $300m, prompting shareholders to fret about what the already cash-rich company has planned. Vague talk about licensing opportunities by management, who refused to say what type of deals they were pursuing,...
- External links 2009-08-11
- Astellas' Current Setback Underscores Need for Pipeline Expansion
- EP Vantage submits: The spectre of approval for generic versions of transplant drug Prograf, which has been stalking Astellas (ALPMF.PK) for some months now, has materialised in the realms of reality with news that Novartis’s NVS Sandoz unit is about to launch a copycat version of the product in...
- External links 2009-08-13
- Lilly's Arzoxifene Defeat: Pharma Giant's Pipeline Looks Awfully Dry Now
- EP Vantage submits: Eli Lilly LLY has finally admitted defeat in its long-running battle to make arzoxifene, a follow-on osteoporosis drug to its own blockbuster Evista, an approvable and commercially viable product. Although the results of a pivotal phase III trial met its primary endpoints, the drug failed on...
- External links 2009-08-20
- Market Jitters Affect Allos
- EP Vantage submits: Usually the endorsement of an FDA advisory panel for approval of your product is greeted with praise from analysts and an uplift in share price. Unfortunately for Allos Therapeutics ALTH, their 10-4 positive recommendation for pralatrexate, now known as Folotyn, for the hard-to-treat blood cancer, peripheral T-cell...
- External links 2009-09-06
- Facet Biotech Should Dig in Its Heels over Biogen Bid
- EP Vantage submits: While most shareholders would, under normal circumstance, jump at a takeover bid that carried a 64% premium, Facet Biotech FACT appears to be sensibly holding out for better terms following an unsolicited $355m approach from Biogen Idec BIIB. Despite the initially impressive share price premium, the...
- External links 2009-09-08
- Glaxo's U.S. Cervarix Approval More Important for Company's Pride than for Sales
- EP Vantage submits: GlaxoSmithKline GSK finally appears set to win approval for its cervical cancer vaccine Cervarix in the US, an event that could now occur in a couple of weeks' time and bring a long and tortuous journey to a conclusion. Having first filed the vaccine in March...
- External links 2009-09-11
- XenoPort's Most Recent Data Points to Larger Opportunity
- EP Vantage submits: XenoPort XNPT received a big boost yesterday from positive data on its lead drug, GSK1838262/XP13512 gabapentin enacarbil, in a neuropathic pain trial, the second attempt by the company and its partner GlaxoSmithKline GSK to prove that this product has much larger potential than currently forecast. ...
- External links 2009-09-18
- Hemispherx Biopharma: Investors Growing Tired of CFS Drug Delays
- EP Vantage submits: In what has definitely not been its finest week, Hemispherx Biopharma HEB has seen its shares fall heavily after being forced to admit that there were still several issues outstanding with its NDA filing for lead drug, Ampligen, that would mean essential paper work for getting approval...
- External links 2009-11-09
- Poniard Pharmaceuticals' Gamble Doesn't Pay Off
- EP Vantage submits: Poniard Pharmaceuticals PARD on Monday stared into the abyss of disappointment. Shares in the US company lost three quarters of their value on news that its platinum-based chemotherapy agent, picoplatin, failed to improve overall survival in patients with lung cancer in a phase III trial, dashing hopes...
- External links 2009-11-18
- King Pharma: FDA Headaches Continue
- EP Vantage submits: As a pain company, King Pharmaceuticals KG might want to get working on a treatment to spare it the agony that the FDA appears intent on continuing to heap upon its head. Yesterday, an advisory committee voted 11-5 not to recommend its heart imaging drug Corvue...
- External links 2009-07-31
- Human Genome Sciences Raises $310m on Huge Share Price
- EP Vantage submits: Carpe diem appears to be the motto of the day for Human Genome Sciences HGSI, which is taking advantage of the huge share price rise it has experienced since announcing positive phase III data for its lupus drug, Benlysta, and raising up to $310m in a share...
- External links 2009-07-31
- Amgen Partners with Glaxo to Distribute Prize Pipeline Product
- EP Vantage submits: Amgen AMGN has finally revealed its commercialisation strategy for osteoporosis treatment, denosumab, one of the most keenly anticipated new drugs set to reach the market for several years, naming GlaxoSmithKline GSK as partner in Europe and other countries. The antibody is considered the most valuable pipeline...
- External links 2009-07-28
- Rigel's Punishment May Prove Short-Sighted
- EP Vantage submits: Rigel Pharmceuticals' RIGL shares have lost almost half their value this week since the release of fresh data from a phase II study of its lead product, R788 in rheumatoid arthritis, which considering the new information was neither overwhelmingly negative, nor entirely new, seems an overly severe...
- External links 2008-10-31
- Human Genome Sciences Awaiting Crucial Albuferon Data
- EP Vantage submits: Recent headlines that Susquehanna analysts have downgraded their rating on Human Genome Sciences HGSI from “positive” to “neutral”, whilst negative for sentiment, may have initially appeared relatively innocuous given the tough financial climate. However, this “neutral” rating masked some pretty damming opinions from the analysts, including: “our...
- External links 2008-11-14
- Amylin Facing Crisis of Confidence
- EP Vantage submits: The plunge in Amylin’s AMLN valuation over the last few months indicates a serious collapse in confidence in the group as a whole, and with a focus on diabetes and obesity, two of the most challenging areas of drug development at the moment, it is not hard...
- External links 2008-11-14
- << Previous
- page 1 of 2
- Next >>
